Drug General Information (ID: DDIEL2DUJA)
Drug Name			Ibritumomab tiuxetan		Drug Info		Ticagrelor		Drug Info
Drug Type		Monoclonal antibody				Small molecule
Therapeutic Class		Antineoplastics				Antiplatelet Agents

Mechanism of Ibritumomab tiuxetan-Ticagrelor Interaction (Severity Level: Moderate)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Ibritumomab tiuxetan				Ticagrelor
Mechanism		Risk of bleeding Antiplatelet effects				Risk of bleeding Antiplatelet
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Ibritumomab tiuxetan and Ticagrelor

Recommended Action
Management		Caution is recommended when these drugs are used concomitantly with ticagrelor or within 24 hours of ticagrelor dosing. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Product Information. Brilinta (ticagrelor). Astra-Zeneca Pharmaceuticals, Wilmington, DE.